The Cambridge, MA-based biotech has one blockbuster-tipped drug already on the market, with another in pivotal studies.

Two years into her tenancy as CEO, Bahija Jallal is on the cusp of taking UK biotech Immunocore from a research and development organization to a company with a burgeoning pipeline and a marketed therapy. She talks to In Vivo about validating the platform, an IPO and creating a commercial footprint.

BioMed X teams with J&J on inflammation, drug delivery research. Stem cell firm Calidi inks licensing deals with U. of Chicago, City of Hope and Northwestern. MD Anderson teams with Blueprint and Hummingbird.

Following last year’s approval in cataplexy for the Xyrem follow-on, Jazz could realize additional revenue of up to $500m annually with the first and only approval in IH, analysts say.